Orrick advised BioAtla on the deal.Clinical-stage biotechnology company BioAtla, Inc. (Nasdaq: BCAB) announced the sale of 9,745,128 shares of its common stock at a price of $6.67…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
